BTG Pactual Asset Management US LLC Takes $532,000 Position in Gilead Sciences, Inc. $GILD

BTG Pactual Asset Management US LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 4,213 shares of the biopharmaceutical company’s stock, valued at approximately $532,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $15,393,785,000. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $2,617,152,000. Legal & General Group Plc acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $918,387,000. Finally, Boston Partners purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $517,808,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 90,000 shares of company stock valued at $12,266,220 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $146.34 on Tuesday. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a 50 day moving average price of $134.68 and a 200 day moving average price of $136.50. The firm has a market capitalization of $181.46 billion, a price-to-earnings ratio of -54.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter last year, the business earned $2.01 EPS. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.5 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analyst Upgrades and Downgrades

Several analysts have commented on GILD shares. Rothschild & Co Redburn lowered their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Daiwa Securities Group reduced their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Needham & Company LLC restated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Barclays lowered their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Twenty-four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.